a:18:{s:4:"name";s:6:"Movfor";s:11:"small_descr";s:54:"Molnupiravir, an Oral Antiviral Treatment for COVID-19";s:14:"small_descr_de";s:0:"";s:14:"small_descr_fr";s:0:"";s:14:"small_descr_es";s:0:"";s:14:"small_descr_it";s:0:"";s:10:"full_descr";s:2120:"<div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Background</h3><p id="__p1" class="p p-first-last">Easily distributed oral antivirals are urgently needed to treat  coronavirus disease-2019 (COVID-19), prevent progression to severe  illness, and block transmission of severe acute respiratory syndrome  coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial  evaluating the safety, tolerability, and antiviral efficacy of  molnupiravir in the treatment of COVID-19.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Methods</h3><p id="__p2" class="p p-first-last">Eligible  participants included outpatients with confirmed SARS-CoV-2 infection  and symptom onset within 7 days. Participants were randomized 1:1 to 200  mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or  placebo, twice-daily for 5 days. Antiviral activity was assessed as time  to undetectable levels of viral RNA by reverse transcriptase polymerase  chain reaction and time to elimination of infectious virus isolation  from nasopharyngeal swabs.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Results</h3><p id="__p3" class="p p-first-last">Among  202 treated participants, virus isolation was significantly lower in  participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%)  at Day 3 (p = 0.02). At Day 5, virus was not isolated from any  participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those  receiving placebo (p = 0.03). Time to viral RNA clearance was decreased  and a greater proportion overall achieved clearance in participants  administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir  was generally well tolerated, with similar numbers of adverse events  across all groups.</p></div><div id="__sec4" class="sec sec-last"><h3 id="__sec4title">Conclusions</h3><p id="__p4" class="p p-first-last">Molnupiravir  is the first oral, direct-acting antiviral shown to be highly effective  at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA  and has a favorable safety and tolerability profile.</p></div></div>";s:13:"full_descr_de";s:0:"";s:13:"full_descr_fr";s:0:"";s:13:"full_descr_es";s:0:"";s:13:"full_descr_it";s:0:"";s:9:"min_price";s:4:"5.55";s:9:"pack_name";s:4:"caps";s:4:"type";s:2:"mg";s:7:"analogs";N;s:8:"synonims";a:10:{i:0;s:9:"Ritonavir";i:1;s:8:"Paxlovid";i:2;s:7:"Monuvir";i:3;s:6:"Molvir";i:4;s:10:"Molenzavir";i:5;s:8:"Lagevrio";i:6;s:8:"Emorivir";i:7;s:5:"Covid";i:8;s:7:"Bexovid";i:9;s:11:"Favipiravir";}s:18:"active_ingredients";N;s:8:"packings";a:1:{i:200;a:5:{i:7646;a:5:{s:10:"id_packing";s:4:"7646";s:5:"count";s:2:"40";s:6:"dosage";d:200;s:14:"price_per_pill";s:3:"7.4";s:4:"name";s:6:"Movfor";}i:7647;a:5:{s:10:"id_packing";s:4:"7647";s:5:"count";s:2:"80";s:6:"dosage";d:200;s:14:"price_per_pill";s:7:"6.24375";s:4:"name";s:6:"Movfor";}i:7648;a:5:{s:10:"id_packing";s:4:"7648";s:5:"count";s:3:"120";s:6:"dosage";d:200;s:14:"price_per_pill";s:7:"5.85833";s:4:"name";s:6:"Movfor";}i:7649;a:5:{s:10:"id_packing";s:4:"7649";s:5:"count";s:3:"160";s:6:"dosage";d:200;s:14:"price_per_pill";s:7:"5.66563";s:4:"name";s:6:"Movfor";}i:7650;a:5:{s:10:"id_packing";s:4:"7650";s:5:"count";s:3:"200";s:6:"dosage";d:200;s:14:"price_per_pill";s:4:"5.55";s:4:"name";s:6:"Movfor";}}}}